BROSSARD, QUEBEC--(Marketwire - Feb. 15, 2011) - DIAGNOS inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, announces today that it has signed a dealership agreement with CenterVue SpA ("CenterVue"), an Italian private corporation, for the distribution of CenterVue's DRS (Digital Retinography System) product in Canada, Mexico, UAE, Oman, Kuwait, Saudi Arabia, Indonesia, Vietnam, Qatar, Bahrain and Brazil ("the territory").
"We are pleased to become a distributor of CenterVue's DRS. At a suggested retail price that offers a major price/performance advantage over major market-leading brands, we believe it will accelerate mass screening projects. The overall quality and ease of use of this non-mydriatic fundus camera (no dilation of the pupil required) is impressive. The agreement provides that, when bundled with our proprietary CARA technology, DIAGNOS has the exclusivity in the territory. CenterVue received in October 2010 FDA approval for the camera. CenterVue's DRS will broaden our CARA offering" said André Larente, CEO of DIAGNOS.
About CenterVue
CenterVue develops leading-edge diagnostic systems and promotes the establishment of screening programs aimed at preventing serious and prevalent diseases. The company realizes medical devices and supplies services to promote the knowledge creation progress, largely on the WEB. Early detection of many diseases, whose prevalence in the population is rapidly progressing, allows to control their evolution, thus dramatically improving the quality of life of the patient. In fact, tests for preventive diagnosis are among the most cost-effective procedures in medicine.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras. CARA is a cost-effective tool for processing large numbers of images, in real-time and has been issued a licence by Health Canada for commercialization in Canada.
About DIAGNOS
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources, healthcare, and entertainment.
For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com. You may also contact our investor relations representative.
Contact Information: DIAGNOS inc.
Andre Larente
President and CEO
1-877-678-8882 or 450-678-8882, ext.: 224
alarente@diagnos.com